Literature DB >> 8744544

Cardiac hypertrophy and failure in hypertension.

D B Johnson1, L J Dell'Italia.   

Abstract

Left ventricular hypertrophy is both a major adaptive response to chronic pressure overload and an important risk factor in patients with hypertension. It is now well appreciated that structural changes in the myocardium are mediated not only by the mechanical stress of pressure overload but also by various neurohormonal substances that exert trophic effects on myocytes and non-myocytes in the heart. Both earlier recognition and improved understanding of cardiac hypertrophy may lead to more effective therapeutic strategies for hypertension. This review focuses on the underlying mechanisms in hypertensive heart disease that lead to heart failure.

Entities:  

Mesh:

Year:  1996        PMID: 8744544     DOI: 10.1097/00041552-199603000-00016

Source DB:  PubMed          Journal:  Curr Opin Nephrol Hypertens        ISSN: 1062-4821            Impact factor:   2.894


  13 in total

Review 1.  Depression and myocardial infarction. Implications for medical prognosis and options for treatment.

Authors:  T J Cleophas
Journal:  Drugs Aging       Date:  1997-08       Impact factor: 3.923

Review 2.  Fluorescence-based force/tension sensors: a novel tool to visualize mechanical forces in structural proteins in live cells.

Authors:  Jun Guo; Frederick Sachs; Fanjie Meng
Journal:  Antioxid Redox Signal       Date:  2014-01-15       Impact factor: 8.401

Review 3.  Cardiorenal disease: a clinical intersection.

Authors:  Vikram Kalra; Sandeep Mahajan; Sanjay Kumar Agarwal; Suresh Chander Tiwari
Journal:  Int Urol Nephrol       Date:  2005       Impact factor: 2.370

Review 4.  Preventing Heart Failure by Treating Systolic Hypertension: What Does the SPRINT Add?

Authors:  Bharathi Upadhya; Richard B Stacey; Dalane W Kitzman
Journal:  Curr Hypertens Rep       Date:  2019-01-18       Impact factor: 5.369

5.  17β-Estradiol and/or estrogen receptor alpha blocks isoproterenol-induced calcium accumulation and hypertrophy via GSK3β/PP2A/NFAT3/ANP pathway.

Authors:  Peiying Pai; Bharath Kumar Velmurugan; Chia-Hua Kuo; Chung-Yi Yen; Tsung-Jung Ho; Yueh-Min Lin; Yu-Feng Chen; Chao-Hung Lai; Cecilia Hsuan Day; Chih-Yang Huang
Journal:  Mol Cell Biochem       Date:  2017-06-02       Impact factor: 3.396

Review 6.  Anemia, chronic renal disease and congestive heart failure--the cardio renal anemia syndrome: the need for cooperation between cardiologists and nephrologists.

Authors:  Donald S Silverberg; Dov Wexler; Adrian Iaina; Shoshana Steinbruch; Y Wollman; Doron Schwartz
Journal:  Int Urol Nephrol       Date:  2006       Impact factor: 2.370

7.  Effect of Intensive Blood Pressure Reduction on Left Ventricular Mass, Structure, Function, and Fibrosis in the SPRINT-HEART.

Authors:  Bharathi Upadhya; Michael V Rocco; Nicholas M Pajewski; Tim Morgan; Joseph Blackshear; William Greg Hundley; Suzanne Oparil; Elsayed Z Soliman; Debbie L Cohen; Craig A Hamilton; Monique E Cho; William J Kostis; Vasilios Papademetriou; Carlos J Rodriguez; Dominic S Raj; Ray Townsend; Sujethra Vasu; Sara Zamanian; Dalane W Kitzman
Journal:  Hypertension       Date:  2019-07-01       Impact factor: 10.190

8.  Effect of Intensive Blood Pressure Lowering on Left Ventricular Hypertrophy in Patients With Hypertension: SPRINT (Systolic Blood Pressure Intervention Trial).

Authors:  Elsayed Z Soliman; Walter T Ambrosius; William C Cushman; Zhu-Ming Zhang; Jeffrey T Bates; Javier A Neyra; Thaddeus Y Carson; Leonardo Tamariz; Lama Ghazi; Monique E Cho; Brian P Shapiro; Jiang He; Lawrence J Fine; Cora E Lewis
Journal:  Circulation       Date:  2017-05-16       Impact factor: 29.690

9.  Cardio-renal anemia syndrome.

Authors:  G Efstratiadis; D Konstantinou; I Chytas; G Vergoulas
Journal:  Hippokratia       Date:  2008-01       Impact factor: 0.471

10.  Left ventricular hypertrophy: major risk factor in patients with hypertension: update and practical clinical applications.

Authors:  Richard E Katholi; Daniel M Couri
Journal:  Int J Hypertens       Date:  2011-06-30       Impact factor: 2.420

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.